



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/00516</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/GB98/01862 <b>(22) International Filing Date:</b> 25 June 1998 (25.06.98) <b>(30) Priority Data:</b> 9713469.6                      25 June 1997 (25.06.97)                      GB <b>(71) Applicant (for all designated States except US):</b> MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LOVELL-BADGE, Robin [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). PEVNY, Laryssa, H. [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). SMITH, Austin [GB/GB]; Centre for Genome Research, University of Edinburgh, East Mains Road, Edinburgh EH9 3WQ (GB). <b>(74) Agents:</b> MASCHIO, Antonio et al.; D. Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> NEURONAL STEM CELL GENE  <b>(57) Abstract</b> <p>The invention relates to a method for isolating a neuroblastic cell from a population of cells comprising the steps of: (a) detecting the expression of the <i>Sox1</i> gene in the cells; and (b) sorting the cells to isolate those cells expressing the <i>Sox1</i> gene, as well as to a method for causing a cell to become committed to the neural pathway comprising administering SOX1 thereto.</p>		

Applicant: Thomas Jessell et al.  
 U.S. Serial No.: 09/654,462  
 Filed: September 1, 2000  
 Exhibit 2

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NEURONAL STEM CELL GENE

The present invention relates to a method of marking, selecting and generating  
5 neuronal stem cells from tissues. In particular, the invention relates to the use of  
the *Sox1* gene for the generation of neuroblasts.

SOX proteins constitute a family of transcription factors related to the mammalian  
testis determining factor SRY through homology within their HMG box DNA  
10 binding domains. In DNA binding studies, SOX proteins exhibit sequence specific  
binding; however, unlike most transcription factors, binding occurs in the minor  
groove resulting in the induction of a dramatic bend within the DNA helix. SOX  
proteins can induce transcription of reporter constructs in vitro and display  
properties of both classical transcription factors and architectural components of  
15 chromatin (reviewed by Pevny and Lovell-Badge (1997) Curr. Opin. Genetics and  
Development, 7:338-344).

Members of the *Sox* gene family are expressed in a variety of embryonic and adult  
tissues, where they appear to be responsible for the development and/or elaboration  
20 of particular cell lineages. *Sry* is transiently expressed in the precursor Sertoli cells  
of the XY genital ridge and is responsible for triggering development of the male  
phenotype (reviewed by Lovell-Badge and Hacker, (1995) Phil. Trans. R. Soc.  
Lond. B 350:205-214). Thus, the lack of *Sry* results in XY females and XX males.  
*Sox9* is expressed in immature chondrocytes and male gonads; mutations in the  
25 human SOX9 gene are associated with Campomelic Dysplasia, a human skeletal  
malformation syndrome, and XY female sex reversal. *Sox4* is expressed in many  
tissues and a null mutation of the gene in mouse results in the absence of mature B  
cells and heart malformations. *Xsox17* genes are involved in endoderm formation in  
*Xenopus* embryos. These functional analyses suggest that *Sox* genes function in  
30 cell fate decisions in diverse developmental pathways.

A subfamily of *Sox* genes, that includes *Sox1*, *Sox2* and *Sox3*, shows expression profiles during vertebrate embryogenesis that suggest the genes could function in the control of cell fate decisions within the early developing nervous system. *Sox2* and *Sox3* begin to be expressed at preimplantation and epiblast stages respectively, and are then restricted to the neuroepithelium. *Sox1* appears only at around the stage of neural induction.

The molecular mechanisms controlling neural induction and determination have begun to be elucidated. The identification by cellular and biochemical methods, of secreted molecules involved in neural induction illustrates the important role of the environment in specifying cell identity. In addition, a number of transcription factors have been isolated which play important roles in the specification and differentiation of neural cell lineages. For example, the characterisation of vertebrate homologues of *Drosophila* proneural and neurogenic genes, which control neural specification in the fly, has revealed analogous molecular mechanisms in vertebrate neural cell fate determination and differentiation. In an *Drosophila*, the expression of basic helix-loop-helix transcription factors of the AS-C complex confirms neural potential on groups of ectodermal cells. Miss expression of a transcription factors involved in a neural cell fate determination is observed to cause abnormalities in neural development.

It is known that *Sox1* expression appears only at around the stage of neural induction in the embryo. The role of SOX1 in embryogenesis is, however, not known.

### Summary of the Invention

It is shown herein that *Sox1* expression correlates with the formation of the neural plate. Moreover, the onset of *Sox1* expression in embryonal carcinoma cells is shown to be dependent on neural induction. Upregulation of *Sox1* expression is itself sufficient to impart a neural fate on pluripotent cells.

In a first aspect of the present invention, there is provided a method for isolating a neuroblastic cell from a population of cells comprising the steps of:

- (a) detecting the expression of the *Sox1* gene in the cells; and
- 5 (b) sorting the cells to isolate those cells expressing the *Sox1* gene.

As set forth in the following description, the *Sox1* gene, which encodes SOX1, is responsible for the specification of neuroblast or neuronal stem cells, as well as acting as a marker for such cells. Expression of *Sox1* is responsible for the  
10 generation of the neuroblastic cell type, which *in vivo* is capable of differentiating into the many different cells and ganglia of the CNS. Moreover, *Sox1* is a unique marker for neuroblasts.

Cells which are identified as expressing this gene, for example by binding to anti-  
15 SOX1 antibodies, by activation of SOX1 dependent ligand-receptor systems or by detection with antisense nucleic acids specific for *Sox1* mRNA, are pluripotent neuroblasts. Such cells can be identified in early embryonic tissue or adult CNS material. Cells can be sorted by affinity techniques, or by cell sorting (such as fluorescence-activated cell sorting) where they are labelled with a suitable label,  
20 such as a fluorophore conjugated to or part of, for example, an antisense nucleic acid molecule or an immunoglobulin.

According to a second aspect of the invention, neuroblast cells can be actively sorted from other cell types by detecting the expression of SOX1 *in vivo* using a  
25 reporter system. Thus, for example, the invention provides a method for isolating a neuroblastic cell from a population of cells, comprising the steps of:

- (a) transfecting the population of cells with a genetic construct comprising a coding sequence encoding a detectable marker operatively linked to the *Sox1* control regions;
- 30 (b) detecting the cells which express the selectable marker; and

(c) sorting the cells which express the selectable marker from the population of cells.

As before, the selectable marker may be any selectable entity, but is preferably a fluorescent or luminescent marker which may be detected and sorted by automated cell sorting approaches. For example, the marker may be GFP or luciferase. Other useful markers include those which are expressed in the cell membrane, thus facilitating cell sorting by affinity means.

10 The genetic construct according to the invention may comprise any promoter and enhancer elements as required, so long as the overall control remains sensitive to SOX1; in other words, no expression of the marker coding sequence should take place in the absence of SOX1. The regulatory sequences of the SOX1 gene are known in the art and have been described in the literature cited herein and  
15 incorporated herein by reference; at least, however, the construct of the invention will comprise a SOX1 binding site. Preferably, the SOX1 control elements are used in their entirety; however, other promoter and enhancer elements may be substituted where they remain under the influence of SOX1.

20 The selectable marker will only be expressed in neuroblastic cells because only these cells express SOX1, which is required for transcription from the *Sox1* control sequences. Preferably, therefore, the expression system used to express the selectable marker is not leaky and expresses a minimal amount of the marker in the absence of SOX1. Techniques for transforming cells with coding genetic constructs  
25 according to the invention, detecting the marker and sorting cells accordingly are known in the art.

The present invention, in a third aspect, provides the use of the *Sox1* coding sequence to transform precursor cells and thereby differentiate neuroblast cells  
30 therefrom. Accordingly, there is provided a method for differentiating one or more

neuroblastic cells from one or more pluripotent precursor cell, comprising the steps of:

(a) transforming the pluripotent precursor cell(s) with a genetic construct comprising a *Sox1* coding sequence operatively linked to suitable control sequences;  
5 and

(b) culturing the cell(s) so as to allow expression of the *Sox1* coding sequence, thereby inducing the cell to differentiate into a neuroblast.

Suitable control sequences for use in the third aspect of the invention are known in  
10 the art and may include inducible or constitutive control sequences. Inducible control sequences have the advantage that *Sox1* expression may be switched off when desired, for example once the cell is to be differentiated into another neural cell. Moreover, once the expression of exogenous *Sox1* has been switched off, successfully differentiated neuroblasts may be identified by virtue of the continued  
15 expression of the endogenous *Sox1* gene.

Precursor cells may be, for example, ES cells, such as human ES cells and cells with similar pluripotent properties derived from germ cells (EG cells). More specific neuronal pluripotent precursors or direct neuroblast precursors may also be  
20 employed.

Neuroblasts obtained according to the invention may be employed in a number of ways. Of course, the expression of *Sox1* has important implications for the study of neural differentiation; the generation and selection of neuroblasts will provide  
25 material for basic research.

Moreover, the invention has medical and diagnostic applications. The detection of *Sox1* expressing cells is important in clinical neurology and in diagnosing and treating cancers of the nervous system. Accordingly, the invention provides a  
30 method for detecting the presence of a neuroblast as described above for diagnostic purposes.

Neural stem cells are also useful for the treatment of neurological disorders, especially for repair of accidentally induced trauma in the CNS or for the correction of congenital or pathological diseases of the CNS.

5

Moreover, in applications involving somatic gene therapy designed to correct a genetic defect in nervous tissue, the removal, treatment and replacement of pluripotent neuroblasts which are actively dividing has clear advantages, providing a constant source of modified neural cells to permanently treat the targeted defect.

10 *Sox1* control sequences may be used specifically to direct transgene expression in neuroblast cells where this is desired. Moreover, gene expression can be directed to neural cell types differentiated from neuroblasts by the use of other control sequences, such as NF-1 control sequences which direct expression of NF-1 in mature neurons *in vivo*.

15

A significant advantage of the methods described herein is that a patient in need of treatment for a neurological disorder can act as a self-donor. In other words, cells may be isolated from the patient and either sorted to extract neuroblasts, or treated in order to differentiate neuroblasts as described, from specific or general precursors.

20

### Detailed Description of the Invention

The present invention relates to a method for isolating, or producing cells which are committed to the neural fate. Accordingly, the term neuroblast, as used herein, refers to any cell or cell line which has commenced differentiation along the neural pathways.

25

The isolation of neuroblastic cells from populations of cells is desirable, in order to obtain cells which are committed to neural pathways, but are not terminally differentiated. Such cells are useful in the study of neuronal differentiation, and in

30



the treatment of diseases such as neurodegenerative diseases, and neural damage, for example occasioned by trauma. Thus, typical populations of cells from which neuroblastic cells may be differentiated include cell populations derived from the CNS of mammals, such as humans, including CNS from adult and foetal sources.

5 Moreover, cell populations derived from tissue cultures may be employed for the isolation of neuroblastic cells.

It has been determined that SOX1 expression is closely associated with the acquisition of neural fate by the ectoderm, both in vitro and in vivo. *In vitro* SOX1

10 expression is initiated within 24 hours after the addition of retinoic acid to pluripotent EC cell aggregates coincident with the induction of neuroepithelial markers such as NESTIN, *Mash1* and *Wnt1*. In mouse and rat embryos expression is restricted to cells of the antero/distal ectoderm. Previous fate mapping studies indicated that this region of the epiblast constitutes the promordium of the nervous

15 system.

Expression of SOX1 is detected throughout the cells of the neural plate and early neural tube along its entire anteroposterior axis. The early and uniform expression of SOX1 throughout the presumptive CNS indicates that SOX1 is activated by

20 neural inducing signals and lends support to the proposal of a two step response of the ectoderm to organiser signals in generating a nervous system: neutralisation followed by regionalisation.

Expression of this *Sox* gene subfamily has been evolutionarily conserved. The

25 *Drosophila* (Nambu and Nambu 1996; Russel et al., 1996) zebrafish (Vriz et al., 1996) and avian (Unwanogho et al., 1995; Streit et al., 1997; Rex et al., 1997) putative orthologues of *Sox1*, *Sox2* and *Sox3* all show expression throughout the neural primordium. Thus, this subfamily of *Sox* genes represents a novel group of transcription factors which can serve as general early neuroepithelial markers.

30

In order to isolate neuroblastic cells, the present invention provides for the detection of *Sox1* therein. As used herein, *Sox1* may be derived from any source, including mammalian sources, avian sources and other vertebrate sources. *Sox1* may also be derived from invertebrate sources.

5

*Sox1* has been cloned from human, chicken and mouse. The sequence of chicken, mouse and human *Sox1* is set forth in SEQ ID.s numbers 1 to 3 herein.

10

The preferred sequence encoding *Sox1* is that encoding human *Sox1* and having substantially the same nucleotide sequence as the sequence in SEQ ID No. 3, with the nucleic acid having the same sequence as the sequence in SEQ ID No. 3 being most preferred. As used herein, nucleotide sequences which are substantially the same share at least about 90% identity. However, in the case of splice variants having e.g. an additional exon sequence homology may be lower.

15

The nucleic acids of the invention, whether used as probes or otherwise, are preferably substantially homologous to the sequence of human *Sox1* as shown in SEQ ID No. 3. As used herein, "homology" means that the two entities share sufficient characteristics for the skilled person to determine that they are similar in origin and function. Preferably, homology is used to refer to sequence identity. Thus, *Sox1* sequences according to the invention preferably retain substantial sequence identity human *Sox1*.

20

"Substantial homology", where homology indicates sequence identity, means more than 40% sequence identity, preferably more than 45% sequence identity and most preferably a sequence identity of 50% or more, as judged by direct sequence alignment and comparison.

25

Sequence homology (or identity) may be determined using any suitable homology algorithm, using for example default parameters. Advantageously, the BLAST algorithm is employed, with parameters set to default values. The BLAST

30

algorithm is described in detail at [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html), which is incorporated herein by reference. The search parameters are defined as follows, and are advantageously set to the defined default parameters.

5 Advantageously, "substantial homology" when assessed by BLAST equates to sequences which match with an EXPECT value of at least 7, preferably at least 9 and most preferably 10 or more. The default threshold for EXPECT in BLAST searching is usually 10.

10 BLAST (Basic Local Alignment Search Tool) is the heuristic search algorithm employed by the programs blastp, blastn, blastx, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin and Altschul (see [http://www.ncbi.nih.gov/BLAST/blast\\_help.html](http://www.ncbi.nih.gov/BLAST/blast_help.html)) with a few enhancements. The BLAST programs were tailored for sequence similarity  
15 searching, for example to identify homologues to a query sequence. The programs are not generally useful for motif-style searching. For a discussion of basic issues in similarity searching of sequence databases, see Altschul et al. (1994) Nature Genetics 6:119-129.

20 The five BLAST programs available at <http://www.ncbi.nlm.nih.gov> perform the following tasks:

**blastp** compares an amino acid query sequence against a protein sequence database;

25 **blastn** compares a nucleotide query sequence against a nucleotide sequence database;

**blastx** compares the six-frame conceptual translation products of a nucleotide query sequence (both strands) against a protein sequence database;

30

**tblastn** compares a protein query sequence against a nucleotide sequence database dynamically translated in all six reading frames (both strands).

**tblastx** compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

BLAST uses the following search parameters:

**HISTOGRAM** Display a histogram of scores for each search; default is yes. (See parameter H in the BLAST Manual).

**DESCRIPTIONS** Restricts the number of short descriptions of matching sequences reported to the number specified; default limit is 100 descriptions. (See parameter V in the manual page). See also **EXPECT** and **CUTOFF**.

**ALIGNMENTS** Restricts database sequences to the number specified for which high-scoring segment pairs (HSPs) are reported; the default limit is 50. If more database sequences than this happen to satisfy the statistical significance threshold for reporting (see **EXPECT** and **CUTOFF** below), only the matches ascribed the greatest statistical significance are reported. (See parameter B in the BLAST Manual).

**EXPECT** The statistical significance threshold for reporting matches against database sequences; the default value is 10, such that 10 matches are expected to be found merely by chance, according to the stochastic model of Karlin and Altschul (1990). If the statistical significance ascribed to a match is greater than the **EXPECT** threshold, the match will not be reported. Lower **EXPECT** thresholds are more stringent, leading to fewer chance matches being reported. Fractional values are acceptable. (See parameter E in the BLAST Manual).

CUTOFF Cutoff score for reporting high-scoring segment pairs. The default value is calculated from the EXPECT value (see above). HSPs are reported for a database sequence only if the statistical significance ascribed to them is at least as high as would be ascribed to a lone HSP having a score equal to the CUTOFF value.

- 5 Higher CUTOFF values are more stringent, leading to fewer chance matches being reported. (See parameter S in the BLAST Manual). Typically, significance thresholds can be more intuitively managed using EXPECT.

- MATRIX Specify an alternate scoring matrix for BLASTP, BLASTX, TBLASTN and TBLASTX. The default matrix is BLOSUM62 (Henikoff & Henikoff, 1992). The valid alternative choices include: PAM40, PAM120, PAM250 and IDENTITY. No alternate scoring matrices are available for BLASTN; specifying the MATRIX directive in BLASTN requests returns an error response.
- 10

- 15 STRAND Restrict a TBLASTN search to just the top or bottom strand of the database sequences; or restrict a BLASTN, BLASTX or TBLASTX search to just reading frames on the top or bottom strand of the query sequence.

- FILTER Mask off segments of the query sequence that have low compositional complexity, as determined by the SEG program of Wootton & Federhen (1993) Computers and Chemistry 17:149-163, or segments consisting of short-periodicity internal repeats, as determined by the XNU program of Claverie & States (1993) Computers and Chemistry 17:191-201, or, for BLASTN, by the DUST program of Tatusov and Lipman (see <http://www.ncbi.nlm.nih.gov>). Filtering can eliminate statistically significant but biologically uninteresting reports from the blast output (e.g., hits against common acidic-, basic- or proline-rich regions), leaving the more biologically interesting regions of the query sequence available for specific matching against database sequences.
- 20
- 25

- 30 Low complexity sequence found by a filter program is substituted using the letter "N" in nucleotide sequence (e.g., "NNNNNNNNNNNNNN") and the letter "X" in

protein sequences (e.g., "XXXXXXXXXX"). Users may turn off filtering by using the "Filter" option on the "Advanced options for the BLAST server" page.

5 Filtering is only applied to the query sequence (or its translation products), not to database sequences. Default filtering is DUST for BLASTN, SEG for other programs.

10 It is not unusual for nothing at all to be masked by SEG, XNU, or both, when applied to sequences in SWISS-PROT, so filtering should not be expected to always yield an effect. Furthermore, in some cases, sequences are masked in their entirety, indicating that the statistical significance of any matches reported against the unfiltered query sequence should be suspect.

15 NCBI-gi Causes NCBI gi identifiers to be shown in the output, in addition to the accession and/or locus name.

Most preferably, sequence comparisons are conducted using the simple BLAST search algorithm provided at <http://www.ncbi.nlm.nih.gov/BLAST>.

20 Preferably, the invention makes use of fragments of the *Sox1*-encoding sequence. Fragments of the nucleic acid sequence of a few nucleotides in length, preferably 5 to 150 nucleotides in length, are especially useful as probes.

25 Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a *Sox1* protein and hybridise to the DNA sequences set forth SEQ ID No. 3, or a selected fragment of said DNA sequence. Preferred are such sequences encoding *Sox1* which hybridise under high-stringency conditions to the sequence of SEQ ID No. 3.

30 Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field.

As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrid which decreases approximately 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na<sup>+</sup> at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 Na<sup>+</sup> pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, et al., eds. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York or Ausubel, et al., eds. (1990) Current Protocols in Molecular Biology, John Wiley & Sons,

Inc.). Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the hybridising pair also play a role.

Advantageously, the invention moreover provides nucleic acid sequence which are  
5 capable of hybridising, under stringent conditions, to a fragment of SEQ. ID. No. 3. Preferably, the fragment is between 15 and 50 bases in length. Advantageously, it is about 25 bases in length.

As will be appreciated by those skilled in the art, the redundancy of the genetic  
10 code allows the design of a large number of sequences encoding human *Sox1*. Any of these sequences may be useful for expressing SOX1 as described below. An advantage of the use of a sequence encoding human SOX1 which is not the human *Sox1* sequence is that the mRNA produced has a different sequence to that of the endogenous *Sox1* mRNA, and may thus be distinguished therefrom. Antisense  
15 oligonucleotides may be designed which are capable of selectively inhibiting the expression of either endogenous or exogenous *Sox1* genes. Degenerate sequences encoding human SOX1 are set forth in SEQ. ID. No. 5.

Given the guidance provided herein, nucleic acids encoding *Sox1* are obtainable  
20 according to methods well known in the art. For example, a nucleic acid encoding *Sox1* is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a genomic library or a suitable cDNA library prepared from a source believed to possess *Sox1* and to express it at a detectable level.

25 Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidite and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the sequence of the nucleic acid complementary to the coding strand is  
30 available. Alternatively, if the target amino acid sequence is known, one may infer



potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

An alternative means to isolate a gene encoding *Sox1* is to use PCR technology as described e.g. in section 14 of Sambrook et al., 1989. This method requires the use of oligonucleotide probes that will hybridise to *Sox1* nucleic acid. Strategies for selection of oligonucleotides are described below.

Libraries are screened with probes or analytical tools designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries suitable means include monoclonal or polyclonal antibodies that recognise and specifically bind to *Sox1*; oligonucleotides of about 20 to 80 bases in length that encode known or suspected *Sox1* cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to oligonucleotides, cDNAs or fragments thereof that encode the same or hybridising DNA; and/or homologous genomic DNAs or fragments thereof.

A nucleic acid encoding *Sox1* may be isolated by screening suitable cDNA or genomic libraries under suitable hybridisation conditions with a probe, i.e. a nucleic acid disclosed herein including oligonucleotides derivable from the sequences set forth in SEQ ID NO. 3. Suitable libraries are commercially available or can be prepared e.g. from cell lines, tissue samples, and the like.

As used herein, a probe is e.g. a single-stranded DNA or RNA that has a sequence of nucleotides that includes between 10 and 50, preferably between 15 and 30 and most preferably at least about 20 contiguous bases that are the same as (or the complement of) an equivalent or greater number of contiguous bases set forth in SEQ ID No. 3. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimised. The nucleotide sequences are usually based on conserved or highly

homologous nucleotide sequences or regions of *Sox1*. The nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.

5

Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. For example, either the full-length cDNA clone disclosed herein or fragments thereof can be used as probes. Preferably, nucleic acid probes of the invention are labelled with suitable label means for ready detection upon hybridisation. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating  $\alpha^{32}\text{P}$  dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labelled with  $\gamma^{32}\text{P}$ -labelled ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling, fluorescent labelling with suitable fluorophores and biotinylation.

After screening the library, e.g. with a portion of DNA including substantially the entire *Sox1*-encoding sequence or a suitable oligonucleotide based on a portion of said DNA, positive clones are identified by detecting a hybridisation signal; the identified clones are characterised by restriction enzyme mapping and/or DNA sequence analysis, and then examined, e.g. by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete *Sox1* (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein.

It is envisaged that Sox 1-encoding sequences can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a SOX1 mutant that has an amino acid sequence differing from the SOX1 sequences as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.

10

Sorting of cells, based upon detection of expression of the *Sox1* gene, may be performed by any technique known in the art, as exemplified above. For example, the cells may be sorted by flow cytometry or FACS. For a general reference, see Flow Cytometry and Cell Sorting: A Laboratory Manual (1992) A. Radbruch (Ed.), Springer Laboratory, New York.

15

Flow cytometry is a powerful method for studying and purifying cells. It has found wide application, particularly in immunology and cell biology: however, the capabilities of the FACS can be applied in many other fields of biology. The acronym F.A.C.S. stands for Fluorescence Activated Cell Sorting, and is used interchangeably with "flow cytometry". The principle of FACS is that individual cells, held in a thin stream of fluid, are passed through one or more laser beams, causing light to be scattered and fluorescent dyes to emit light at various frequencies. Photomultiplier tubes (PMT) convert light to electrical signals, which are interpreted by software to generate data about the cells. Sub-populations of cells with defined characteristics can be identified and automatically sorted from the suspension at very high purity (~100%).

20

25

FACS machines collect fluorescence signals in one to several channels corresponding to different laser excitation and fluorescence emission wavelengths. Fluorescent labelling allows the investigation of many aspects of cell structure and

30

function. The most widely used application is immunofluorescence: the staining of cells with antibodies conjugated to fluorescent dyes such as fluorescein and phycoerythrin. This method is often used to label molecules on the cell surface, but antibodies can also be directed at targets within the cell. In direct  
5 immunofluorescence, an antibody to a particular molecule, the SOX1 polypeptide, is directly conjugated to a fluorescent dye. Cells can then be stained in one step. In indirect immunofluorescence, the primary antibody is not labelled, but a second fluorescently conjugated antibody is added which is specific for the first antibody: for example, if the anti-SOX1 antibody is a mouse IgG, then the second antibody  
10 could be a rat or rabbit antibody raised against mouse IgG.

FACS can be used to measure gene expression in cells transfected with recombinant DNA encoding SOX1. This can be achieved directly, by labelling of the protein product, or indirectly by using a reporter gene in the construct. Examples of  
15 reporter genes are  $\beta$ -galactosidase and Green Fluorescent Protein (GFP).  $\beta$ -galactosidase activity can be detected by FACS using fluorogenic substrates such as fluorescein digalactoside (FDG). FDG is introduced into cells by hypotonic shock, and is cleaved by the enzyme to generate a fluorescent product, which is trapped within the cell. One enzyme can therefore generate a large amount of fluorescent  
20 product. Cells expressing GFP constructs will fluoresce without the addition of a substrate. Mutants of GFP are available which have different excitation frequencies, but which emit fluorescence in the same channel. In a two-laser FACS machine, it is possible to distinguish cells which are excited by the different lasers and therefore assay two transfections at the same time.

25

Alternative means of cell sorting may also be employed. For example, the invention comprises the use of nucleic acid probes complementary to *Sox1* mRNA. Such probes can be used to identify cells expressing *Sox1* individually, such that they may subsequently be sorted either manually, or using FACS sorting. Nucleic  
30 acid probes complementary to *Sox1* mRNA may be prepared according to the

teaching set forth above, using the general procedures as described by Sambrook et al (1989).

5 In a preferred embodiment, the invention comprises the use of an antisense nucleic acid molecule, complementary to *Sox1* mRNA, conjugated to a fluorophore which may be used in FACS cell sorting.

10 Suitable imaging agents for use with FACS may be delivered to the cells by any suitable technique, including simple exposure thereto in cell culture, delivery of transiently expressing nucleic acids by viral or non-viral vector means, liposome-mediated transfer of nucleic acids or imaging agents, and the like.

15 The invention, in certain embodiments, includes antibodies specifically recognising and binding to SOX1. For example, such antibodies may be generated against the SOX1 having the amino acid sequences set forth in SEQ ID No. 4. Alternatively, SOX1 or SOX1 fragments (which may also be synthesised by in vitro methods) are fused (by recombinant expression or an in vitro peptidyl bond) to an immunogenic polypeptide and this fusion polypeptide, in turn, is used to raise antibodies against a SOX1 epitope.

20

Anti-SOX1 antibodies may be recovered from the serum of immunised animals. Monoclonal antibodies may be prepared from cells from immunised animals in the conventional manner.

25 The antibodies of the invention are useful for identifying SOX1 in neural cells expressing *Sox1*, in accordance with the present invention.

30 Antibodies according to the invention may be whole antibodies of natural classes, such as IgE and IgM antibodies, but are preferably IgG antibodies. Moreover, the invention includes antibody fragments, such as Fab, F(ab')<sub>2</sub>, Fv and ScFv. Small fragments, such as Fv and ScFv, possess advantageous properties for diagnostic and

therapeutic applications on account of their small size and consequent superior tissue distribution.

The antibodies may comprise a label. Especially preferred are labels which allow the imaging of the antibody in neural cells in vivo. Such labels may be radioactive labels or radioopaque labels, such as metal particles, which are readily visualisable within tissues. Moreover, they may be fluorescent labels or other labels which are visualisable in tissues and which may be used for cell sorting.

Recombinant DNA technology may be used to improve the antibodies of the invention. Thus, chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimised by humanising the antibodies by CDR grafting [see European Patent Application 0 239 400 (Winter)] and, optionally, framework modification.

Antibodies according to the invention may be obtained from animal serum, or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

Therefore, the present invention includes a process for the production of an antibody according to the invention comprising culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding said protein, and isolating said protein.

Multiplication of hybridoma cells or mammalian host cells in vitro is carried out in suitable culture media, which are the customary standard culture media, for example

Dulbecco's Modified Eagle Medium (DMEM) or RPMI 1640 medium, optionally replenished by a mammalian serum, e.g. foetal calf serum, or trace elements and growth sustaining supplements, e.g. feeder cells such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages, 2-aminoethanol, insulin, transferrin, low density lipoprotein, oleic acid, or the like. Multiplication of host cells which are bacterial cells or yeast cells is likewise carried out in suitable culture media known in the art, for example for bacteria in medium LB, NZCYM, NZYM, NZM, Terrific Broth, SOB, SOC, 2 x YT, or M9 Minimal Medium, and for yeast in medium YPD, YEPD, Minimal Medium, or Complete Minimal Dropout Medium.

In vitro production provides relatively pure antibody preparations and allows scale-up to give large amounts of the desired antibodies. Techniques for bacterial cell, yeast or mammalian cell cultivation are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor or in a continuous stirrer reactor, or immobilised or entrapped cell culture, e.g. in hollow fibres, microcapsules, on agarose microbeads or ceramic cartridges.

Large quantities of the desired antibodies can also be obtained by multiplying mammalian cells in vivo. For this purpose, hybridoma cells producing the desired antibodies are injected into histocompatible mammals to cause growth of antibody-producing tumours. Optionally, the animals are primed with a hydrocarbon, especially mineral oils such as pristane (tetramethyl-pentadecane), prior to the injection. After one to three weeks, the antibodies are isolated from the body fluids of those mammals. For example, hybridoma cells obtained by fusion of suitable myeloma cells with antibody-producing spleen cells from Balb/c mice, or transfected cells derived from hybridoma cell line Sp2/0 that produce the desired antibodies are injected intraperitoneally into Balb/c mice optionally pre-treated with pristane, and, after one to two weeks, ascitic fluid is taken from the animals.

The cell culture supernatants are screened for the desired antibodies, preferentially by immunofluorescent staining of cells expressing SOX1, by immunoblotting, by an enzyme immunoassay, e.g. a sandwich assay or a dot-assay, or a radioimmunoassay.

5

For isolation of the antibodies, the immunoglobulins in the culture supernatants or in the ascitic fluid may be concentrated, e.g. by precipitation with ammonium sulphate, dialysis against hygroscopic material such as polyethylene glycol, filtration through selective membranes, or the like. If necessary and/or desired, the antibodies are purified by the customary chromatography methods, for example gel  
10 filtration, ion-exchange chromatography, chromatography over DEAE-cellulose and/or (immuno-)affinity chromatography, e.g. affinity chromatography with SOX1 protein or with Protein-A.

15 The invention further concerns hybridoma cells secreting the monoclonal antibodies of the invention. The preferred hybridoma cells of the invention are genetically stable, secrete monoclonal antibodies of the invention of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.

20 The invention also concerns a process for the preparation of a hybridoma cell line secreting monoclonal antibodies directed SOX1, characterised in that a suitable mammal, for example a Balb/c mouse, is immunised with purified SOX1 protein, an antigenic carrier containing purified SOX1 or with cells bearing SOX1, antibody-producing cells of the immunised mammal are fused with cells of a suitable  
25 myeloma cell line, the hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example spleen cells of Balb/c mice immunised with cells bearing SOX1 are fused with cells of the myeloma cell line PAI or the myeloma cell line Sp2/0-Ag14, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are  
30 cloned.



Preferred is a process for the preparation of a hybridoma cell line, characterised in that Balb/c mice are immunised by injecting subcutaneously and/or intraperitoneally between 10 and 10<sup>7</sup> and 10<sup>8</sup> cells of human tumour origin which express SOX1 containing a suitable adjuvant several times, e.g. four to six times, over several  
5 months, e.g. between two and four months, and spleen cells from the immunised mice are taken two to four days after the last injection and fused with cells of the myeloma cell line PAI in the presence of a fusion promoter, preferably polyethylene glycol. Preferably the myeloma cells are fused with a three- to twentyfold excess of spleen cells from the immunised mice in a solution containing about 30 % to about  
10 50 % polyethylene glycol of a molecular weight around 4000. After the fusion the cells are expanded in suitable culture media as described hereinbefore, supplemented with a selection medium, for example HAT medium, at regular intervals in order to prevent normal myeloma cells from overgrowing the desired hybridoma cells.

15 The invention also concerns recombinant DNAs comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to the extracellular domain of SOX1 as described hereinbefore. By definition such DNAs comprise coding single stranded DNAs, double stranded  
20 DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

Furthermore, DNA encoding a heavy chain variable domain and/or for a light chain variable domain of antibodies directed SOX1 can be enzymatically or chemically  
25 synthesised DNA having the authentic DNA sequence coding for a heavy chain variable domain and/or for the light chain variable domain, or a mutant thereof. A mutant of the authentic DNA is a DNA encoding a heavy chain variable domain and/or a light chain variable domain of the above-mentioned antibodies in which one or more amino acids are deleted or exchanged with one or more other amino  
30 acids. Preferably said modification(s) are outside the CDRs of the heavy chain variable domain and/or of the light chain variable domain of the antibody. Such a

mutant DNA is also intended to be a silent mutant wherein one or more nucleotides are replaced by other nucleotides with the new codons coding for the same amino acid(s). Such a mutant sequence is also a degenerated sequence. Degenerated sequences are degenerated within the meaning of the genetic code in that an unlimited number of nucleotides are replaced by other nucleotides without resulting in a change of the amino acid sequence originally encoded. Such degenerated sequences may be useful due to their different restriction sites and/or frequency of particular codons which are preferred by the specific host, particularly *E. coli*, to obtain an optimal expression of the heavy chain murine variable domain and/or a light chain murine variable domain.

The term mutant is intended to include a DNA mutant obtained by *in vitro* mutagenesis of the authentic DNA according to methods known in the art.

For the assembly of complete tetrameric immunoglobulin molecules and the expression of chimeric antibodies, the recombinant DNA inserts coding for heavy and light chain variable domains are fused with the corresponding DNAs coding for heavy and light chain constant domains, then transferred into appropriate host cells, for example after incorporation into hybrid vectors.

The invention therefore also concerns recombinant DNAs comprising an insert coding for a heavy chain murine variable domain of an antibody directed SOX1 fused to a human constant domain  $\gamma$ , for example  $\gamma 1$ ,  $\gamma 2$ ,  $\gamma 3$  or  $\gamma 4$ , preferably  $\gamma 1$  or  $\gamma 4$ . Likewise the invention concerns recombinant DNAs comprising an insert coding for a light chain murine variable domain of an antibody directed to SOX1 fused to a human constant domain  $\kappa$  or  $\lambda$ , preferably  $\kappa$ .

In another embodiment the invention pertains to recombinant nucleic acids wherein the heavy chain variable domain and the light chain variable domain are linked by way of a DNA insert coding for a spacer group, optionally comprising a signal sequence facilitating the processing of the antibody in the host cell and/or a DNA

coding for a peptide facilitating the purification of the antibody and/or a DNA coding for a cleavage site and/or a DNA coding for a peptide spacer and/or a DNA coding for an effector molecule, such as a label.

- 5 According to a further aspect, and as referred to above, neuroblastic cells may be actively sorted from other cell types by detecting *Sox1* expression in vivo using a reporter system. For example, such a reporter system may comprise a readily identifiable marker under the control of a *Sox1* activated expression system. Fluorescent markers, which can be detected and sorted by FACS, are preferred.
- 10 Especially preferred are GFP and luciferase.

Alternatively, an *in vivo* construct expressing a reporter may be placed under the control of the *Sox1* control sequences themselves. These sequences are activated at the same time as *Sox1* expression is activated, and therefore mark the transition into

15 the neural pathway with the same accuracy as *Sox1*. Advantageously, the *Sox1* control sequences used are human *Sox1* control sequences. Preferably, they comprise nucleotides 1 to 60 of SEQ. ID. No. 3.

In general, reporter constructs useful for detecting neural cells by expression of a

20 reporter gene may be constructed the general teaching of Sambrook et al (1989). Typically, constructs according to the invention comprise a promoter by *Sox1*, and a coding sequence encoding the desired reporter constructs, for example of GFP or luciferase. Vectors encoding GFP and luciferase are known in the art and available commercially.

25

SOX proteins bind to a sequence motif (A/T A/T CAA A/T G) (SEQ. ID. No. 6) with high affinity. Accordingly, constructs according to the invention advantageously comprise the above-recited motif, or a functional equivalent thereof, operably linked to a gene encoding a selectable marker.

30

When transfected into cells which are potentially express *Sox1*, constructs according to the invention will be activated specifically by *Sox1* expression. Therefore, the selectable marker will be expressed once the cell enters the neural differentiation pathway and *Sox1* expression is induced. This allows cells entering the neural differentiation pathway to be sorted by FACS.

In a still further aspect, the present invention relates to the transfection of pluripotent precursor cells, capable of differentiating into neural cells, with a vector expressing *Sox1*. By such means, pluripotent precursor cells may be induced to differentiate along the neural pathway, becoming precursor neurons capable of differentiating into a variety of neural tissues.

Herein, terms such as "transfection", "transformation" and the like are not intended to be significant, except to indicate that nucleic acid is transferred to a cell or organism in functional form. Such terms include various means of transferring nucleic acids to cells, including transfection with  $\text{CaPO}_4$ , electroporation, viral transduction, lipofection, delivery using liposomes and other delivery vehicles, biolistics and the like.

Suitable pluripotent precursor cells may be derived from a number of sources. For example, ES cells, such as human ES cells and cells derived from a Germ cells (EG cells) may be derived from embryonal tissue. Alternatively, pluripotent cells may be prepared by a retrodifferentiation, by the administration of growth factors or otherwise (see WO 96/23870), or by cloning, such as by nuclear transfer from an adult cell to a pluripotent cell such as an ovum.

Human stem cells of neural lineage may be isolated from human tissues directly. Alternatively, stem cells from non-human animals, such as rodents, may be used.

Neural stem cells may also be propagated in vitro, for example as described in Snyder *et al.* (1996) Clinical Neuroscience 3: 310-316, and Martinez-Serrano *et al.*,

(1996) Clinical Neuroscience 3:301-309. Moreover, pluripotent cell lines such as the N-Tera II cell line which are capable of differentiating into neural cells upon stimulation with agents such as retinoic acid are also responsive to *Sox1* stimulation.

5 The cDNA or genomic DNA encoding native or mutant SOX1, or a label under to control of *Sox1* sequences or a sequence transactivatable by SOX1, can be incorporated into vectors according too techniques known in the art. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for expression. Selection and use of such vehicles are  
10 well within the skill of the artisan. The vector components generally include, but are not limited to, one or more of the following: an origin of replication, one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence.

15 Most expression vectors are shuttle vectors, i.e. they are capable of replication in at least one class of organisms but can be transfected into another class of organisms for expression. For example, a vector is cloned in *E. coli* and then the same vector is transfected into mammalian cells even though it is not capable of replicating independently of the host cell chromosome.

20 Advantageously, an expression and cloning vector may contain a selection gene, also referred to as selectable marker, other than that intended for marking *Sox1*-expressing cells. This gene may encode a protein necessary for the survival of growth of transformed host cells grown in a selective culture medium. Host cells  
25 not transformed with the vector containing the selection gene will not survive in the culture medium. Typical selection genes encode proteins that confer resistance to antibiotics and other toxins, e.g. ampicillin, neomycin, methotrexate or tetracycline, complement auxotrophic deficiencies, or supply critical nutrients not available from complex media.

30

Since the replication of vectors is conveniently done in *E. coli*, an *E. coli* genetic marker and an *E. coli* origin of replication are advantageously included. These can be obtained from *E. coli* plasmids, such as pBR322, Bluescript® vector or a pUC plasmid, e.g. pUC18 or pUC19, which contain both *E. coli* replication origin and  
5 *E. coli* genetic marker conferring resistance to antibiotics, such as ampicillin.

Expression vectors usually contain a promoter that is recognised by the host organism and is operably linked to SOX1, or label-encoding, nucleic acid. Such a promoter may be inducible by factors which induce *Sox1*, or by *Sox1* itself. The  
10 promoters are operably linked to DNA encoding SOX1 by removing the promoter from the source DNA and inserting the isolated promoter sequence into the vector. Both the native SOX1 promoter sequence and many heterologous promoters may be used to direct amplification and/or expression of SOX1 DNA. The term "operably linked" refers to a juxtaposition wherein the components described are in a  
15 relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

20 Control sequences, comprising a promoter and optionally enhancer(s), may be derived from the human or other *Sox1* genes. Alternatively, any suitable promoter may be used, when placed under the control of a SOX1-inducible element. In such a construct, the promoter selected should have a low residual level of activity, such as to minimise expression of the label in the absence of *Sox1* expression.

25

The vectors may also contain sequences necessary for the termination of transcription and for stabilising the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments  
30 in the untranslated portion of the mRNA encoding SOX1 or the label.

An expression vector includes any vector capable of expressing SOX1 or label-encoding nucleic acids that are operatively linked with regulatory sequences, such as promoter regions, that are capable of expression of such DNAs. Thus, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector, that upon introduction into an appropriate host cell, results in expression of the cloned DNA. Appropriate expression vectors are well known to those with ordinary skill in the art and include those that are replicable in eukaryotic and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. For example, DNAs encoding SOX1 may be inserted into a vector suitable for expression of cDNAs in mammalian cells, e.g. a CMV enhancer-based vector such as pEVRF (Matthias, et al., (1989) NAR 17, 6418).

Particularly useful for practising the present invention are expression vectors that provide for the transient expression of DNA encoding SOX1 or a label in mammalian cells. Transient expression usually involves the use of an expression vector that is able to replicate efficiently in a host cell, such that the host cell accumulates many copies of the expression vector, and, in turn, synthesises high levels of SOX1 or a label. For the purposes of the present invention, transient expression systems are useful e.g. for identifying SOX1 expressing cells or for inducing a pluripotent cell to differentiate.

Construction of vectors according to the invention employs conventional techniques, for example as described in Sambrook *et al.*, 1989. Isolated plasmids or DNA fragments are cleaved, tailored, and religated in the form desired to generate the plasmids required. If desired, analysis to confirm correct sequences in the constructed plasmids is performed in a known fashion. Suitable methods for constructing expression vectors, preparing in vitro transcripts, introducing DNA into host cells, and performing analyses for assessing gene expression and function are known to those skilled in the art. Gene presence, amplification and/or expression may be measured in a sample directly, for example, by conventional

Southern blotting, Northern blotting to quantitate the transcription of mRNA, dot blotting (DNA or RNA analysis), or in situ hybridisation, using an appropriately labelled probe which may be based on a sequence provided herein. Those skilled in the art will readily envisage how these methods may be modified, if desired.

5

The invention is described, for the purpose of illustration only, in the following examples.

## MATERIAL AND METHODS

- 10 **Manufacture of SOX1 polyclonal antibodies:** A 622bp HincII fragment encoding sequences C-terminal of the HMG box of SOX1 (207 a.a.) is fused in frame to the bacterial GST gene in the construct pGEX3X. Fusion protein is induced and purified as described by Smith and Johnson (1988) Gene 67:31-40. rabbits are treated with a course of injections as recommended by Smith and Johnson (1988):
- 15 each injection contains 250µg of fusion protein. Two final bleeds, FB43 and FB44, are obtained from the rabbits prior to the preparation of polyclonal sera.

- Immunocytochemistry:** Embryos, P19 cells and neural plate explants are examined using standard techniques (Placzek *et al.*, (1993) Development 117:205-218).
- 20 Antibodies are used at the following dilutions: anti-SOX1 PAb (1:500); K2 anti-HNF3β MAb (1:40); 6G3 anti-FP3 MAb (1:10); anti-3A10 MAb (1:10); anti-2H3(Neurofilament-160) MAb (1:10); 4D5 anti-Islet-1 MAb (1:1000); anti-SSEA1 MAb (1:80) (Hybridoma Bank); anti-NESTINE MAb (1:10) (Hybridoma Bank); anti-BrDU MAb (1:500) (Sigma); Appropriate secondary antibodies (TAGO and
- 25 Sigma) are conjugated to fluorescein isothiocyanate (FITC), Cy2 or Cy3.

- BrDU analysis:** Pregnant mice are injected intraperitoneally with 50µg/g of body weight of 5-bromo-2deoxyuridine (BrDU) (Sigma) in 0.9% NaCl and sacrificed two hours after injection. Embryos are fixed and sectioned as described above. The
- 30 slides are washed twice in PBS, and incubated in 0.2% HCl at 37°C for 30 minutes, then rinsed thoroughly with PBS, followed by three rinses with PBS/0.1%



Trinton/1% heat inactivated goat serum (P-T-G). Monoclonal anti-BrDU (1:500 dilution in P-T-G) is applied to the sections and incubated at 4°C overnight. Sequential sections are incubated in SOX1 antibody (1:500 dilution in P-T-G) at 4°C overnight. The slides are washed twice in P-T-G, then incubated in the appropriate secondary antibody for 30 minutes at room temperature, washed with P-T-G and mounted.

**P19 cell cultured and retinoic acid treatment:** P19 cells are cultured as previously described (Rudnichy and McBurney, 1987). To induce differentiation, cells are allowed to aggregate in bacterial grade petri dishes alone, in the presence of 1µM retinoic acid or in the presence of 1µM retinoic acid or in the presence of 5mM IPTG. After 4 days of aggregation in the presence of inducing agents, cells are plated on tissue culture chamber slides. The cells are allowed to adhere and grow for 4-5 days, with media changes every 24 hours. For immunofluorescence, cells are grown on tissue culture chamber slides coated with 0.1% gelatin, washed once with PBS, fixed at room temperature in 1x MEMFA for 1 hour, washed in P-T-G twice; then stained with appropriate antibody.

**Cell counting analysis:** For cell counting experiments P19 transfectant cell lines are induced to differentiate, plated on gelatine coated slides, fixed at room temperature in 1xMEMFA for one hour at day 6-8 for neurons. Cells are stained with Neurofilament (2H3) antibody and photographed using an Olympus fluorescence microscope. Cell counts are expressed as percentages of total cells in a field. Eight fields from two different experiments are counted for each P19 clone.

**Plasmids and transfection:** To construct the SOX1 expression vector, pRSVopSox1, the POP113CAT operator vector (Stratagene) is digested with NotI, end-filled Kpn/Stu (position 431-1694) fragment of the Sox1 cDNA. The P3'SS, eukaryotic Lac repressor expressing vector (obtained from Stratagene) is transfected into P19 cells by lipofection. Stable transformants are selected in 250 µg/ml of hygromycin. Expanded clones (250) are isolated and examined for expression of

the Lac repressor by indirect immunofluorescence with anti-lac PAb (Stratagene). Four cell lines are isolated (P3'SS-10, 13, 22 and 47) which show ubiquitous and constitutive expression of the Lac repressor. P3'SS-10 is chosen for the subsequent experiments. P3'SS-10 is then transfected with pRSVop*Sox1* by lipofection. Stable clones are selected using 500µg/ml G481. 250 clones are expanded and analysed for inducible *Sox1* expression by RNase protection and immunocytochemistry with SOX1 antibody.

**RNase protection assays:** Total RNA is prepared from P19 cells and RNase protection assays are carried out using 5µg of P19 cell RAN as described by Capel *et al.*, (1993) Cell 73:1019-1030. Anti-sense labelled probes are derived from the 396 bp SmaI-BspHI fragment (position 1467-1863) of the *Sox1* cDNA, a 215bp BsaI exon 4 specific fragment of *Wnt1* cDNA, a PvuII digest of the *Mash1* cDNA (Johnson *et al.*, (1992) Development 114:75-87) and a NotI digest of SAP D cDNA is used as a loading control (Dresser *et al.*, (1995) Hum. Mol. Genet. 4:1613-1618).

**RT-PCR:** Total RNA is prepared from P19 cells as described by Capel *et al.*, (1993). Reverse transcription, PCR reaction, and priming is performed as described by Okabe *et al.*, (1996).

**Rat lateral neural plate explants:** Lateral neural plates (LNP) are isolated from days 8.5-9.0 rat embryos from prospective hindbrain and spinal cord regions as previously described (Placzek *et al.*, 1993). Notochord explants are dissected from HH stage 608 chick embryos as previously described (Placzek *et al.*, 1993). Explants are embedded in collagen and cultured (Placzek *et al.*, 1993) for 24, 48 and 96 hours. Purified rat SHH-N (Ericson *et al.*, (1996) Cell 87:661-673) is added to cultures at concentrations within the effective ranges used in other assays (Ericson *et al.*, 1996)

**EXAMPLE 1****SOX1 IS EXPRESSED DURING EARLY NEURAL DEVELOPMENT**

SOX1 expression during mouse and rat neurulation is analysed using a rabbit  
5 polyclonal antibody against the SOX1 C-terminal region. In the mouse, expression  
of SOX1 is first detected at 7.5 days post coitum (*dpc*) in the anterior half of the  
late-streak egg cylinder. Cross-sections through the embryo at this stage reveal  
expression in columnar ectodermal cells, which appear to define the neural plate,  
while cells located more laterally are negative. Thus, SOX1 expression at this stage  
10 is specific to the neural plate. SOX1 is maintained in all neuroepithelial cells along  
the entire anteroposterior axis as the neural plate bends (8.0-8.5 dpc, as shown in  
cross-sections of a 2 somite mouse embryos where *Sox1* expression is limited to  
neural folds) and fuses to form the neural tube (9.0-9.5 dpc, where *Sox1* labelling is  
seen to be restricted to the neural tube in cross-sections of 10-12 somite mouse  
15 embryos). The pattern of expression of SOX1 in the rat is similar to that in the  
mouse. The expression of SOX1 throughout the neural plate and early neural tube  
implies a similarity amongst these cells.

After neural tube closure, neuroepithelial cells begin to differentiate into defined  
20 classes of neurons at specific dorsoventral (D/V) positions within the spinal cord  
(Altman and Bayer (1984) *Adv. Anat. Embryol. Cell Biol.* 85:32-46; Tanabe and  
Jessell, (1996) *Science* 274:1115-1123). As development proceeds, *Sox1* is  
downregulated in a stereotyped manner in cells along D/V axis of the neural tube.  
In the spinal cord, expressions first downregulated in cells that occupy the ventral  
25 midline (cross-sections of the thoracic region of 20 somite mouse embryos reveal a  
lack of SOX1 staining in this area), then the ventral motor horns (corresponding  
lack of staining being visible in cross section of 30-35 somite embryos) and  
subsequently the dorsal regions. These regions appear to correlate with floor plate,  
motor neurons and sensory relay interneurons, respectively.

30

To ascertain this a series of antibody double-labelling experiments are performed in rat embryos. The SOX1 antibody is used in combination with a panel of antigenic markers which identify cells of the floor plate and mature neurons (Neurofilament (NF-1): labelled with contrasting colour markers and visualised in an E11 rat embryo). Expression of SOX1 and expression of these markers is almost entirely mutually exclusive. In the ventral spinal cord or the 10.0-12.0 *dpc* mouse embryo, SOX1 expression is maintained only in 'region X' (Yamada *et al.*, (1991) Cell 64:635-647), as revealed by immunolabelling of two streams of cells located between the differentiated floor plate and ventral motor horns in 30-35 somite embryos. Eventually, by 13.5 *dpc*, SOX1 expression is restricted to a thin ventricular zone in the CNS. SOX1 expression is not detected in the peripheral nervous system (PNS). These expression profiles suggest that SOX1 is expressed by early neural cells in the CNS and is downregulated in the developing neural tube coincident with neural differentiation.

15

## EXAMPLE 2

### SOX1 MARKS PROLIFERATION CELLS WITHIN THE EMBRYONIC NEURAL TUBE

The uniform expression of SOX1 in the neural plate and early neural tube followed by its down regulation along the D/V axis and restriction to the ventricular zone is reminiscent of the pattern of cell proliferation in the developing central nervous system (Sauer, (1935) J. Comp. Neurol. 62:377-405; Fujita, (1963) J. Comp. Neurol. 120: 37-42; Altman and Bayer, 1984). In the neural plate and early neural tube, proliferating progenitor cells are organised in a pseudostratified epithelium in which the processes of these cells extend from the inner luminal to the outer mantle surface. At later stages the neural tube becomes progressively thicker and can be divided into different zones. The proliferating CNS progenitors are largely restricted to the inner ventricular zone (VZ) around the lumen. They begin to migrate away from the lumen while in S-phase, and after completing their final

30

mitosis, migrate to the outer layer, the marginal zone (MZ). In the 10.5 dpc mouse embryo, SOX1 expression is detected, using an anti-SOX1 antibody, throughout the pseudostratified epithelium of the posterior neural tube and is restricted to the ventricular zone in more mature anterior region of the neural tube. In order to evaluate the relationship between SOX1 expression and proliferating CNS cells are directly assayed proliferation by monitoring the incorporation of bromodeoxyuridine (BrDU) with an anti-BrDU antibody. Pregnant mouse females at 10.5 dpc are injected with BrDU two hours prior to dissection to detect proliferating cells. Embryos are then fixed, sectioned and double-labelled for BrDU incorporation and SOX1 expression. Similar to SOX1 expressing cells, those that incorporate BrDU are found throughout the posterior neural tube in 10.5 dpc mouse embryos and lie in the ventricular zone of the anterior neural tube. All cells that incorporate BrDU also express SOX1. SOX1-positive cells that do not incorporate BrDU are restricted to the luminal surface of the ventricular zone. In contrast, no SOX1 nor BrDU-positive cells are detected in the outer marginal zone. These results show that SOX1 is expressed in dividing neuroepithelial cells within the embryonic CNS.

### EXAMPLE 3

#### SOX1 IS DOWNREGULATED IN COMMITTED CELLS

The mutual exclusion of SOX1 and markers of committed differentiated cells such as Islet1 (Pfaff *et al.*, (1996) Cell 84:1-20) raises the possibility that the downregulation of SOX1 may be a pre-requisite step for the differentiation in neural plate explants *in vitro*. Isolated neural plates explants are cultured with known inducers of ventral neural cells, namely the notochord and purified Sonic Hedgehog protein. The expression of SOX1 and incorporation of BrDU is then compared to the expression of three markers of ventral cells, Islet1, FP3 and HNF3 $\beta$ . Consistent with our observations *in vivo* both the expression of SOX1 and Islet1 as well as SOX1 and FP3 is mutually exclusive in neural plate explants cultured adjacent to notochord (n=8) or in the presence of purified Sonic Hedgehog protein as seen in E9 rat neural plate tissue cultured with Sonic Hedgehog protein for 48

hours and stained with anti-SOX1 and anti-Islet1 antibodies. Similarly, the incorporation of both BrDU and Islet1 as well as BrDU and FP3 (detected using an anti-FP3 antibody) is mutually exclusive. In contrast, the domain of expression of HNF3 $\beta$  is found to extend beyond that of FP3 and into the region of BrDU positive cells.

To determine whether a similar population of cells could be detected *in vivo* embryos are analysed, and for co-expression of FP3 and HNF3 $\beta$  and for co-expression of BrDU and HNF3 $\beta$ . We find that medial floor plate cells co-express HNF3 $\beta$  and FP3 but do not incorporate BrDU, whereas lateral floor plate cells express only HNF3 $\beta$  and incorporate BrDU. HNF3 $\beta$  thus provides a marker for cells that are mitotically active but have begun to differentiate.

These cells, occupying the medial regions of the floor plate, express HNF3 $\beta$  but not SOX1. In contrast cells occupying lateral regions of the floor plate co-express HNF3 $\beta$  and SOX1. These observations, together with the mutually exclusive expression of SOX1 with Islet 1 and FP3 in ventral neural cells provide evidence that SOX1 is downregulated as cells exit mitosis and not at the onset of cell differentiation.

#### EXAMPLE 4

#### SOX1 EXPRESSION IS ASSOCIATED WITH NEURAL DIFFERENTIATION

Neural induction is accompanied by the onset of new gene expression which in turn enables the formation of neural rather than epidermal tissue. The early and apparently uniform expression of SOX1 in neural cells, together with observations that *Sox* genes may affect cell lineage decisions, raises the possibility that SOX1 expression is an early response to neural inducing signals and that its expression may be involved in directing cells towards a neural fate. To address whether SOX1 plays a role in establishing neural fate in response to A P19 cell culture system is

used as an *in vivo* model system in which to analyse SOX1 expression and the effects of its misexpression.

P19 cells are an embryonal carcinoma cell line with the ability to differentiate into all three germ layers (McBurney, (1993) *Int. J. dev. Biol.* 37:135-140). In the undifferentiated state P19 cells morphologically resemble an uncommitted primitive ectodermal cell and express the cell surface antigen SSEA-1. These cells have a very low rate of spontaneous differentiation when grown in a monolayer in the absence of chemical inducers. P19 cells grown as aggregates, however, differentiate partially into endodermal cells. Furthermore, with the addition of retinoic acid, aggregated P19 cells differentiate into neuroepithelial-like cells (Jones-Villeneuve *et al.*, (1982) *J. Cell. Biol.* 94:253-262). These express neuroepithelial markers such as NCAM, intermediate filament NESRIN, MASHI (Johnson *et al.*, 1992) and WNT1 (St. Arnaud *et al.*, (1989) *Oncogene* 4:1077-1080). When plated onto a substrate, about 15% of these cells differentiate into mature neurons expressing Neurofilament. Thus, in this *in vitro* model system retinoic acid acts as a "neural inducer".

Initially, the expression of *Sox1* in P19 cells is examined by both RNase protection and immunocytochemistry. The features of *Sox1* expression in P19 cells are similar to those observed in prospective neural tissue *in vivo*. *Sox1* mRNA and protein can not be detected in undifferentiated P19 cells which express the cell-surface antigen SSEA1 when analysed using anti-SOX1 and anti-SSEA antibodies, and by RNase protection. Similarly, when P19 cells are differentiated as aggregates without the addition of chemical inducers, SOX1 is not expressed as determined by RNase protection. In contrast, SOX1 is rapidly induced during neural differentiation when aggregated P19 cells are differentiated in the presence of retinoic acid. *Sox1* thus behaves similarly to other neuroepithelial markers such as *Mash 1* and *Wnt 1*, the transcripts of which are detected in retinoic acid-treated P19 cells by RNase protection.

When retinoic acid-treated P19 cell aggregates are plated onto tissue culture substrate, about 15% of the cells differentiate into mature process-bearing, Neurofilament-expressing neurons. Double-label immunofluorescence is used to simultaneously detect SOX1 and Neurofilament, to examine the expression of SOX1 in P19 cells displaying a fully differentiated neuronal morphology. SOX1 immunoreactivity is not detected in process-bearing Neurofilament-positive neurons. Thus, as in vivo, SOX1 is expressed by P19 cells when they first assume a neural fate but it is then downregulated with their differentiation.

## 10 EXAMPLE 5

### USE OF SOX1 TO DIRECT CELLS TO A NEURAL FATE

The previous data suggest that in P19 cells, as in vivo, SOX1 expression is induced at a time when neuroepithelial cells begin to differentiate. If SOX1 plays a role in directing cells towards the neural fate, expression of SOX1 in P19 cells may be able to substitute for retinoic acid to initiate neural differentiation. Endogenous SOX1 is accordingly activated in P19 cells using an inducible eukaryotic lac repressor-operator expression system. To establish this system a clonal line of P19 cells is generated which constitutively and ubiquitously expresses the lac repressor. This parent line (P3'SS-10) is transfected with pRSVop*Sox1*, a vector containing the *Sox1* cDNA under the regulation of an inducible RSV promoter and stable lines are established. In the uninduced state, without the addition of isopropyl- $\beta$ -d-thiogalactase (IPTG) these lines express high levels of the lac repressor that binds to operon sites upstream of the RSV promoter and thus blocks transcription of *Sox1*. Upon addition of IPTG a conformational change occurs, decreasing the affinity of the repressor and resulting in the activation of pRSVop*Sox1*. Approximately 250 clones of transfectants are isolated in the repressed state. Using RNase protection and immunocytochemistry assays three clones are selected (708-13, 708-16 and 708-21) that express high levels of RSVop*Sox1* in response to IPTG.



The pluripotentiality of these clones is not compromised by the transfection and selection. All three lines express SSEA1 in the uninduced state. Furthermore, when aggregated in retinoic acid the uninduced clones initiate expression of endogenous *Sox1* and differentiate into mature Neurofilament-expressing neurons  
5 after plating, in a manner similar to wild-type P19 untransfected cells.

In order to address whether expression of SOX1 can initiate neural differentiation and thereby substitute for the requirement of retinoic acid, it is determined whether the transient exposure of P19 aggregates to retinoic acid can be replaced by a  
10 transient induction of RSVop*Sox1*, through addition of IPTG. Wildtype P19 cells and transfected P19 clones (708-13, 708-16 and 708-21) are cultured as aggregates for 96 hours with or without the addition of IPTG. After 96 hours RNA is isolated from half of the aggregates for RNase protection and/or RT-PCR assays. The remaining aggregates are plated onto tissue culture substrate, allowed to  
15 differentiate for three days without further addition of IPTG and then scored for the expression of a panel of neuroepithelial and neuronal markers by immunocytochemistry. These conditions are the same as those used for retinoic acid-induced differentiation of wildtype P19 cells. After 96 hours the clones induced to express RSVop*Sox1* with IPTG express endogenous *Sox1* and *Mash1*.  
20 The expression of these two neuroepithelial markers is similar to that seen in wildtype cells induced with retinoic acid. In addition the IPTG induced clones expressed NESTIN and *Hoxa7* (Mahon et al., (1988) Development (Suppl.) 187-195). Further differentiation of the transiently-induced clones on substrate showed the presence of mature neurons as demonstrated by Neurofilament-positive, 3A10-  
25 positive and Islet1-positive cells. All three clones 708-13, 708-16 and 708-21 differentiate in this matter although the number of mature neurons produced is variable. The number of differentiated neurons formed in the IPTG induced clones is estimated by determining the number of Neurofilament-positive cells in a given field of cells. The number of neurons ranges from 6-8% for clone 708-13, 15-20%  
30 for clone 708-16 and 20-25% for clone 708-21. The latter two clones show uniform and ubiquitous induction of SOX1 expression whereas expression in clone 708-13 is

not in all cells. In addition, the transiently induced clones generate GFAP-positive cells indicating glial cell differentiation. None of these markers is detected in wildtype P19 cells cultured in the presence of IPTG or in clones 708-13, 708-16, and 708-21 cultured in the absence of IPTG. The expression of SOX1, both in vivo  
5 and in vitro, is mutually exclusive with mature neuronal markers such as Neurofilament and Islet1. To examine SOX1 expression in the mature neurons generated in the transiently-induced clones, double-label immunofluorescence is used to simultaneously detect SOX1 and Neurofilament. No SOX1 expression could be detected in cells positive for Neurofilament in these cultures.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

(A) NAME: MEDICAL RESEARCH COUNCIL  
(B) STREET: 20 PARK CRESCENT  
(C) CITY: LONDON  
(E) COUNTRY: UK  
(F) POSTAL CODE (ZIP): W1N 4AL

10

(ii) TITLE OF INVENTION: NEURONAL STEM CELL GENE

15

(iii) NUMBER OF SEQUENCES: 6

## (iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

20

## (2) INFORMATION FOR SEQ ID NO: 1:

25

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2312 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

35

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Gallus gallus

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

45 CCGCAGAGCG CGGCAGGACG GGCACACGCC GGGCGCAGCA CCGCGAAGCA CCGCGCAGCC 60  
CCGCGCAGCC CCGCACCTGT TTGCGCGCCC CGCGCCCGGA GCGGCCCCCG GCAGCGGGAG 120  
GACGCCGGCA GCGCCGCCGC CGCCGCTCCT CGCATGTGCG GTGCCTCCCC GCCGCCCGGC 180  
50 GCCGGAGGGA AGTGAGGAAG CCCCCTGAAT GTACAGCATG ATGATGGAGA CGGACTTGCA 240  
CTCGCCCGGC GGAGCCCCGG CGCCCGGCGG CGGCCTCTCG GGGCAGAGCG GCGCGGGCGG 300  
55 CGGCGGCGGC GGCGGCGGCG GCGGCGGGGG CAAAGCGGGG CAGGACCGCG TGAAGCGCCC 360

	CATGAACGCC	TTCATGGTGT	GGTCGCGGGG	GCAGCGGCGG	AAGATGGCCC	AGGAGAATCC	420
	CAAGATGCAC	AACTCGGAGA	TCAGCAAGCG	GCTGGGCGCC	GAGTGGAAGG	TGATGTCGGA	480
5	GGCCGAGAAG	CGGCCTTTCA	TCGACGAGGC	GAAGCGGCTG	CGGGCGCTGC	ACATGAAGGA	540
	GCACCCGGAT	TATAAATACC	GGCCCCGGCG	GAAGACCAAG	ACGCTGCTCA	AGAAGGACAA	600
	GTACTCGCTG	GCCGGAGGGC	TGCTGGGCGC	CGGCCCGGCC	GCGGGCGGCC	CTCCCGCCGT	660
10	CGGCGTGGGC	ATGGGCGTCG	GCGTGATCCC	CGGCGGAGTC	GGGCAGCGGC	TGGAGAGCCC	720
	CGGCGGGGCG	GCGGGCGGCG	GCTACGCGCA	CATGAACGGG	TGGGCCAACG	GCGCCTACCC	780
15	GGGCTCGGTG	GCGGGCGGCG	CGGCGGCGGC	GGCGATGATG	CAGGAGGCGC	AGCTCGCCTA	840
	CGGGCAGCAC	CCGGGCGGCG	GGGGGCACCC	GCACCACCCG	CACCCGCACC	ACCCGCACCA	900
	CCCGCACAAAC	CCGCAGCCCA	TGCACCGCTA	CGACATGGGC	GCGCTGCAGT	ACAGCCCCAT	960
20	CTCCAAC TCG	CAGGGCTACG	TGAGCGCCTC	GCCCTCGGGC	TACGGCGCGC	TGCCCTACGG	1020
	CTCGCAGCCC	CACCAGAACT	CGGCGGCCGC	GGCGGCGGCG	GCGGCGGCGG	CGGCGGCCGC	1080
25	CTCGTCGGGC	GCGCTGGGCG	CGCTGGGCTC	GCTCGTCAAG	TCGGAGCCCA	GCGTGAGCCC	1140
	GCCCGTCACC	TCGCACTCGC	GGGCCCCGTG	CCCCGGGGAC	CTGCGGGAGA	TGATCAGTAT	1200
	GTACTTACCG	GGCGGCGAGG	GAGGCGACCC	GGCGGCCGCC	GCCGCCCAGA	GCCGCCTGCA	1260
30	CTCCCTGCCC	CAGCACTACC	AGAGCGCCAG	CACGGGGGTC	AACGGCACCG	TCCCCTTGAC	1320
	GCACATCTGA	GCGGCCCCCG	AGCGGCCCCG	GAGCGGCGCG	GAGGGCCCCG	GCCCGGGCCC	1380
35	CGCAGGACTG	CGGCCCCGCC	GCCGCCCCGC	GCCCGCCGCC	CCCCTTCGTT	TTTGCCTTTC	1440
	ATTCGGCTCC	TTCCCGCCCT	CCCCCTCCCT	CCTTCCTTTT	TTTGT TTTGT	TTTGT TTTGT	1500
	TTTTCTTTTC	TTCCTTTTTC	TACAGAAATG	TTTTGATGTT	CTTGTAATAA	TAATAAATAA	1560
40	TAATAATAAT	AATAACGAGA	GAGAGAGAAA	AAGAAGGTAA	CGGTGGCTTT	ACTGACCTTT	1620
	TTGTTTTTAG	GAGGACCAGA	TCCCGGGA CT	AGTTTTAGAC	TGAAC TTCTG	TGTTTTATCG	1680
45	AGACTTTTTG	TACAGTATTT	ATCATTACCC	CCAGAGACAC	AGAGCGTTTA	TTTGCAAAAAG	1740
	AGGAGAGAGA	GAGGATTAAA	AAACAAAAAC	AAACAAACAA	ACAAACAAAA	AAAGACGGCG	1800
	ACGAAAAGAC	AAAACCATCG	CCGCTGACAC	CCAAAGTTTC	GGCGGGGCCA	ACTTTCGGGC	1860
50	TGCGCTTCGC	CCCGCACCGC	CTCACTGCAA	ACGGAGCCGA	CGGGGAGCGG	TGCTCGTTCC	1920
	TTCTTCGCAC	ACCCCAAAAC	AGCACCACGA	GTTTCCGTAG	ATGTTCTCGC	GCTTTTCCTT	1980
55	TTTGGTTGGG	TTATTTCCGC	TGCTTTATTT	ATACAACTTT	TTCTTCTTCT	TCCTTCTTCT	2040

CCGAGGTTGC AACGTTTGCT TGATTTTAT TTTATTTAT TTTTTTTCT GGGTTATGTG 2100  
 AAACTTTACT GTATCTGCAT CATTTCGGTT TGTTCCTC CCCCCCCCC CCTTTTTTTT 2160  
 5 TTTTTTTACA TTTTTTTGTA TCATCTCGTG TAAATGCATT GTGAAATAAT TTTTATCTAG 2220  
 GCGTGGCGAG GGAACCCAGA CTGTACATAG TTTACTAAAA AGCCTTTCTG CTAAACAGAA 2280  
 ACCCGAAGGA TCGTTCAT TTTGAGTTAA AT 2312

10

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 2376 base pairs  
 15 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

20

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

25

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Mus musculus

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

ACAGGAACGG AGACTTCGAG CCGAGAAGAG GAGGCAGCGA ACCCTGCGTC GGGCCCAGGG 60  
 GCACCGCTTC AGACCCAGAA AGTGGAGCCT CAACTTGGCC ACGACTGCAC CTGTTTGCAC 120  
 35 AGTTCAGCCC TGAGTGACCG GACGGCAGCA ATCAACCTGG CCATCGGCCT CTTTGGCAAG 180  
 TGGTTTGTGC ACCGGGAGAA ACTTCCACC TGCAGCTGG ACCCGCGCTA AGTGCGTGTG 240  
 40 CTTTTCCTC TTTTGTGTTG TTGTTGTTGT TGTGGCCTCC ACCCAACCCC CTTCTCTCCG 300  
 CTAGGCACCC ACCGCACACA CACCCCCCCC CCCAGTCTCT CTGGGCTGAT CCTCTCTCCA 360  
 CCCACCCACC CCCACCCGGC CGTCTATGCT CCAGGCCCTC TCTTTCGGT ACCGGTGAAC 420  
 45 CCGCTAGCCG CCCAGATGTA CAGCATGATG ATGGAGACCG ACCTGCACTC GCCCGCGGGC 480  
 GCCCAGGCGC CCACGAACCT CTCGGGCCCC GCGGGGGCGC GCGGGGGCGG CGGTGGGGGC 540  
 50 GGGGGCGGCG GCGGCGGCGG GGGCACCAAG GCCAACCAGG ATCGGGTCAA GCGGCCCCATG 600  
 AACGCCTTCA TGGTGTGGTC CCGCGGACAG CGGCGCAAGA TGGCCCAGGA AAACCCCAAG 660  
 ATGCACAACCT CGGAGATCAG CAAGCGCCTC GGGGCCGAGT GGAAGGTCAT GTCCGAGGCC 720  
 55 GAGAAGCGGC CGTTCATCGA CGAGGCCAAG AGACTGCGCG CGCTGCACAT GAAGGAACAC 780

CCGGATTACA AGTACCGGCC GCGCCGCAAG ACCAAGACGC TGCTCAAGAA GGACAAGTAC 840  
TCGCTGGCCG GCGGGCTGCT AGCGGCCGGC GCGGGTGGCG GCGGCGCGGC CGTGGCCATG 900  
5 GGTGTGGGCG TGGGCGTCGG GCGGCGGGCG GTGGGCCAGC GCTTGGAGAG CCCAGGCGGC 960  
GCGGCGGGAG GAGGCTACGC GCATGTCAAC GGCTGGGCTA ACGGCGCCTA CCCC GGCTCG 1020  
10 GTGGCCGCGG CGGCTGCGGC CGCGGCCATG ATGCAGGAGG CACAGCTGGC CTACGGGCAG 1080  
CACCCAGGCG CGGGCGGCCG GCACCCGCAC GCACACCCGG CGCACCCGCA CCCGCACCAT 1140  
CCGCACGCGC ATCCTCACAA CCCGCAGCCC ATGCACCGCT ACGACATGGG CGCGCTGCAG 1200  
15 TACAGCCCCA TCTCCAACTC TCAGGGCTAC ATGAGCGCGT CGCCTTCGGG CTACGGCGGC 1260  
ATCCCTTACG GCGCCGCGGC CGCCGCCGCC GCCGCTGCGG GCGGCGCGCA CCAGAACTCG 1320  
20 GCGGTGGCGG CAGCGGCAGC CGCGGCAGCC GCGTCGTCGG GGGCCCTGGG CGCCCTCGGA 1380  
TCTCTGGTCA AGTCGGAGCC GAGCGGCAGT CCGCCGGCCC CGGCTCACTC ACGGGCACCG 1440  
TGTCCCGGGG ACCTGCGCGA GATGATCAGC ATGTACCTGC CGGCCGGCGA GGGTGGCGAC 1500  
25 CCGGCGGGCG CAGCGGCTGC GCGGGCCCAA AGCCGGCTGC ACTCGCTGCC ACAGCACTAC 1560  
CAGGGCGCGG GCGCGGGCGT CAACGGCACG GTGCCCCTGA CGCACATCTA GCGCCGCGGG 1620  
30 GACGCCGGGG AACTGCGGC TTAAGGCCGG CGCCCCGGCG ACGAAGAGCG AGGCCTGCGC 1680  
CCCAGCCTCC AGAGCCCGAC TTTGTACCGA GGTCCCCGCG CTCTCGATAA AAGGCCGCTC 1740  
TGGAGAGCCG AGCGCCAGGT GACATCTGCC CCCATCACCT TCCCCAGGAC TCCGAGGCGC 1800  
35 TGACACCAGA CTGGCCTCTT AGACTGAACT TTGGTGT TTT CATGAGACCT TTTGTACAGT 1860  
ATTTATCGTC CGCAGAGGAG GCACACAGCG TTTTCTCGGC TTCGGAGGAC AAAAGACAAA 1920  
40 AACCAGCGA GCGGATGCCA ACTTTTGTAT GACTGCCGGC TCTGTAACCT TTTCCGGGGT 1980  
TTACTTCCCG CCAGCTCTTC TGCCTGAGGC CGAGTGACGG ACCTCGAGCC CTTCTCACTT 2040  
GTTATAAATC TAAGTAAGGC AGATCCAAAC ATTTACAAGT TTTTGTAGT TGTTACCGCT 2100  
45 CTTTTGGGTT GGTGGTTAA TTTATACCGC AATCCCCTCT CAGACGGTGG AGTTATATTC 2160  
TGGGTTTTGT AAATCTCTGT ATCCGAGCAT TTCCAATTTT TTGTTTTGTT TTGTATTATT 2220  
50 TCTTGTAAT GCGTTGTGAC ATTTTATTT TAGGCGTTGC GATACGGGGG GAAGAGGAGT 2280  
CGGATGTTGT ACATAGCCTG CAAGTCTTTC ATCTAAAAGC AAAACAAAG AGAGATACCC 2340  
CCAAAATGCA TCAAATTTGA ACAATACATT TAAGAG 2376  
55

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 1542 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:  
 (A) ORGANISM: Homo sapiens

(ix) FEATURE:  
 (A) NAME/KEY: CDS  
 (B) LOCATION: 60..1223

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```

25 CCGGCCGTCT ATCTCCAGGC CCTCTCCTCG CGGTGCCGGT GAACCCGCCA GCCGCCCCG      59
   ATG TAC AGC ATG ATG ATG GAG ACC GAC CTG CAC TCG CCC GGC GGC GCC      107
   Met Tyr Ser Met Met Met Glu Thr Asp Leu His Ser Pro Gly Gly Ala
     1             5             10             15

30 CAG GCC CCC ACG AAC CTC TCG GGC CCC GCC GGG GCG GGC GGC GGC GGG      155
   Gln Ala Pro Thr Asn Leu Ser Gly Pro Ala Gly Ala Gly Gly Gly Gly
           20             25             30

35 GGC GGA GGC GGG GGC GGC GGC GGC GGC GGG GGC GCC AAG GCC AAC CAG      203
   Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Lys Ala Asn Gln
       35             40             45

40 GAC CGG GTC AAA CGG CCC ATG AAC GCC TTC ATG GTG TGG TCC CGC GGG      251
   Asp Arg Val Lys Arg Pro Met Asn Ala Phe Met Val Trp Ser Arg Gly
       50             55             60

45 CAG CGG CGC AAG ATG GCC CAG GAG AAC CCC AAG ATG CAC AAC TCG GAG      299
   Gln Arg Arg Lys Met Ala Gln Glu Asn Pro Lys Met His Asn Ser Glu
       65             70             75             80

50 ATC AGC AAG CGC CTG GGG GCC GAG TGG AAG GTC ATG TCC GAG GCC GAG      347
   Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys Val Met Ser Glu Ala Glu
           85             90             95

55 AAG CGG CCG TTC ATC GAC GAG GCC AAG CGG CTG CGC GCG CTG CAC ATG      395
   Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg Leu Arg Ala Leu His Met
           100            105            110

   AAG GAG CAC CCG GAT TAC AAG TAC CGG CCG CGC CGC AAG ACC AAG ACG      443
   Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro Arg Arg Lys Thr Lys Thr
       115             120             125

```

	CTG	CTC	AAG	AAG	GAC	AAG	TAC	TCG	CTG	GCC	GGC	GGG	CTC	CTG	GCG	GCC	491
	Leu	Leu	Lys	Lys	Asp	Lys	Tyr	Ser	Leu	Ala	Gly	Gly	Leu	Leu	Ala	Ala	
		130					135					140					
5	GGC	GCG	GGT	GGC	GGC	GGC	GCG	GCT	GTG	GCC	ATG	GGC	GTG	GGC	GTG	GGC	539
	Gly	Ala	Gly	Gly	Gly	Gly	Ala	Ala	Val	Ala	Met	Gly	Val	Gly	Val	Gly	
	145					150					155					160	
10	GTG	GGC	GCG	GCG	CCC	GTG	GGC	CAG	CGC	CTG	GAG	AGC	CCA	GGC	GGC	GCG	587
	Val	Gly	Ala	Ala	Pro	Val	Gly	Gln	Arg	Leu	Glu	Ser	Pro	Gly	Gly	Ala	
					165					170						175	
15	GCG	GGC	GGC	GCG	TAC	GCG	CAC	GTC	AAC	GGC	TGG	GCC	AAC	GGC	GCC	TAC	635
	Ala	Gly	Gly	Ala	Tyr	Ala	His	Val	Asn	Gly	Trp	Ala	Asn	Gly	Ala	Tyr	
				180						185						190	
20	CCC	GGC	TCG	GTG	GCG	GCC	GCG	GCG	GCC	GCC	GCG	GCC	ATG	ATG	CAG	GAG	683
	Pro	Gly	Ser	Val	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Met	Met	Gln	Glu	
			195						200					205			
25	GCG	CAG	CTG	GCC	TAC	GGG	CAG	CAC	CCC	GGC	GCG	GGC	GGC	GCG	CAC	CCG	731
	Ala	Gln	Leu	Ala	Tyr	Gly	Gln	His	Pro	Gly	Ala	Gly	Gly	Ala	His	Pro	
		210						215					220				
30	CAC	CGC	ACC	CCG	GCG	CAC	CCG	CAC	CCG	CAC	CAC	CCG	CAC	GCG	CAC	CCG	779
	His	Arg	Thr	Pro	Ala	His	Pro	His	Pro	His	His	Pro	His	Ala	His	Pro	
		225					230					235				240	
35	CAC	AAC	CCG	CAG	CCC	ATG	CAC	CGC	TAC	GAC	ATG	GGC	GCG	CTG	CAG	TAC	827
	His	Asn	Pro	Gln	Pro	Met	His	Arg	Tyr	Asp	Met	Gly	Ala	Leu	Gln	Tyr	
					245					250						255	
40	AGC	CCC	ATC	TCC	AAC	TCG	CAG	GGC	TAC	ATG	AGC	GCG	TCG	CCC	TCG	GGC	875
	Ser	Pro	Ile	Ser	Asn	Ser	Gln	Gly	Tyr	Met	Ser	Ala	Ser	Pro	Ser	Gly	
				260					265						270		
45	TAC	GGC	GGC	CTC	CCC	TAC	GGC	GCC	GCG	GCC	GCC	GCC	GCC	GCC	GCG	CAC	923
	Tyr	Gly	Gly	Leu	Pro	Tyr	Gly	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	His	
			275						280					285			
50	CAG	AAC	TCG	GCC	GTG	GCG	GCG	GCG	GCG	GCG	GCG	GCG	GCC	GCG	TCG	TCG	971
	Gln	Asn	Ser	Ala	Val	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ser	Ser	
		290						295					300				
55	GGC	GCC	CTG	GGC	GCG	CTG	GGC	TCT	CTG	GTG	AAG	TCG	GAG	CCC	AGC	GGC	1019
	Gly	Ala	Leu	Gly	Ala	Leu	Gly	Ser	Leu	Val	Lys	Ser	Glu	Pro	Ser	Gly	
		305					310					315				320	
55	AGC	CCG	CCC	GCC	CCA	GCG	CAC	TCG	CGG	GCG	CCG	TGC	CCC	GGG	GAC	CTG	1067
	Ser	Pro	Pro	Ala	Pro	Ala	His	Ser	Arg	Ala	Pro	Cys	Pro	Gly	Asp	Leu	
					325					330						335	
55	CGC	GAG	ATG	ATC	AGC	ATG	TAC	TTG	CCC	GCC	GGC	GAG	GGG	GGC	GAC	CCG	1115
	Arg	Glu	Met	Ile	Ser	Met	Tyr	Leu	Pro	Ala	Gly	Glu	Gly	Gly	Asp	Pro	
				340						345						350	



GCG GCG GCA GCA GCG GCC GCG GCG CAG AGC CGG CTG CAC TCG CTG CCG 1163  
 Ala Ala Ala Ala Ala Ala Ala Ala Ala Gln Ser Arg Leu His Ser Leu Pro  
 355 360 365

5 CAG CAC TAC CAG GGC GCG GGC GCG GGC GTG AAC GGC ACG GTG CCC CTG 1211  
 Gln His Tyr Gln Gly Ala Gly Ala Gly Val Asn Gly Thr Val Pro Leu  
 370 375 380

10 ACG CAC ATC TAG CGCCTTCGGG ACGCCGGGGA CTCTGCGGCG GCGACCCACG 1263  
 Thr His Ile \*  
 385

15 AGCTCGCGGC CCGCGCCCCG CTCCCGCCCC GCCCCGGCGC GCGGTGGCTT TTGTATCAGA 1323  
 CGTTCCACACA TTCTTGTC AA AAGGAAAATA CTGGAGACGA ACGCCGGGTG ACGCGTGTCC 1383  
 CCCACTCACC TTCCCCGGAG ACCCTGGCGA CCGCCGGGCG CTGACACCAG ACTTGTTTGA 1443

20 GACTGAACTT CGGTGTTTTT TTGAGACTTT TGTACAGTAT TTATCACCTA CGGAGGAAGC 1503  
 GGAAGCGTTT TCTTTGCTCG AGGGACAAAA AATGCAAAA 1542

25 (2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 388 amino acids  
 (B) TYPE: amino acid  
 30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein  
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

35 Met Tyr Ser Met Met Met Glu Thr Asp Leu His Ser Pro Gly Gly Ala  
 1 5 10 15  
 Gln Ala Pro Thr Asn Leu Ser Gly Pro Ala Gly Ala Gly Gly Gly Gly  
 20 25 30  
 40 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Lys Ala Asn Gln  
 35 40 45  
 Asp Arg Val Lys Arg Pro Met Asn Ala Phe Met Val Trp Ser Arg Gly  
 45 50 55 60  
 Gln Arg Arg Lys Met Ala Gln Glu Asn Pro Lys Met His Asn Ser Glu  
 65 70 75 80  
 50 Ile Ser Lys Arg Leu Gly Ala Glu Trp Lys Val Met Ser Glu Ala Glu  
 85 90 95  
 Lys Arg Pro Phe Ile Asp Glu Ala Lys Arg Leu Arg Ala Leu His Met  
 100 105 110  
 55 Lys Glu His Pro Asp Tyr Lys Tyr Arg Pro Arg Arg Lys Thr Lys Thr

	115		120		125											
	Leu	Leu	Lys	Lys	Asp	Lys	Tyr	Ser	Leu	Ala	Gly	Gly	Leu	Leu	Ala	Ala
	130						135					140				
5	Gly	Ala	Gly	Gly	Gly	Gly	Ala	Ala	Val	Ala	Met	Gly	Val	Gly	Val	Gly
	145					150				155						160
	Val	Gly	Ala	Ala	Pro	Val	Gly	Gln	Arg	Leu	Glu	Ser	Pro	Gly	Gly	Ala
10					165					170					175	
	Ala	Gly	Gly	Ala	Tyr	Ala	His	Val	Asn	Gly	Trp	Ala	Asn	Gly	Ala	Tyr
				180					185					190		
15	Pro	Gly	Ser	Val	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Met	Met	Gln	Glu
		195						200					205			
	Ala	Gln	Leu	Ala	Tyr	Gly	Gln	His	Pro	Gly	Ala	Gly	Gly	Ala	His	Pro
20		210					215					220				
	His	Arg	Thr	Pro	Ala	His	Pro	His	Pro	His	His	Pro	His	Ala	His	Pro
	225					230					235					240
	His	Asn	Pro	Gln	Pro	Met	His	Arg	Tyr	Asp	Met	Gly	Ala	Leu	Gln	Tyr
25					245					250					255	
	Ser	Pro	Ile	Ser	Asn	Ser	Gln	Gly	Tyr	Met	Ser	Ala	Ser	Pro	Ser	Gly
				260					265					270		
30	Tyr	Gly	Gly	Leu	Pro	Tyr	Gly	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	His
		275						280						285		
	Gln	Asn	Ser	Ala	Val	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ser
35		290					295						300			
	Gly	Ala	Leu	Gly	Ala	Leu	Gly	Ser	Leu	Val	Lys	Ser	Glu	Pro	Ser	Gly
	305					310					315					320
	Ser	Pro	Pro	Ala	Pro	Ala	His	Ser	Arg	Ala	Pro	Cys	Pro	Gly	Asp	Leu
40				325						330					335	
	Arg	Glu	Met	Ile	Ser	Met	Tyr	Leu	Pro	Ala	Gly	Glu	Gly	Gly	Asp	Pro
				340					345					350		
45	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Gln	Ser	Arg	Leu	His	Ser	Leu	Pro
		355						360					365			
	Gln	His	Tyr	Gln	Gly	Ala	Gly	Ala	Gly	Val	Asn	Gly	Thr	Val	Pro	Leu
50		370					375					380				
	Thr	His	Ile	*												
	385															

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1161 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: RNA

(iii) HYPOTHETICAL: YES

10 (iv) ANTI-SENSE: NO

(ix) FEATURE:  
    (A) NAME/KEY: variation  
15      (B) LOCATION:replace(7..9, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(28..30, "cun")

20 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(34..36, "agy")

25 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(64..66, "cun")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
30      (B) LOCATION:replace(67..69, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
35      (B) LOCATION:replace(148..150, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(157..159, "cgn")

40 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(184..186, "agy")

45 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(187..189, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
50      (B) LOCATION:replace(196..198, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
55      (B) LOCATION:replace(199..201, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(235..237, "agy")

5 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(250..252, "cgn")

10 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(244..246, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
15 (B) LOCATION:replace(253..255, "cun")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
20 (B) LOCATION:replace(277..279, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(291..294, "cgn")

25 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(316..318, "cgn")

(ix) FEATURE:  
30 (A) NAME/KEY: variation  
    (B) LOCATION:replace(319..321, "cun")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
35 (B) LOCATION:replace(322..324, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
40 (B) LOCATION:replace(328..330, "cun")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(361..363, "cgn")

45 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(367..369, "cgn")

(ix) FEATURE:  
50 (A) NAME/KEY: variation  
    (B) LOCATION:replace(370..372, "cgn")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
55 (B) LOCATION:replace(385..387, "cun")

- (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(388..390, "cun")
- 5      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(406..408, "agy")
- 10     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(409..411, "cun")
- 15     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(421..423, "cun")
- 20     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(424..426, "cun")
- 25     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(505..507, "cgn")
- 30     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(508..510, "cun")
- 35     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(513..515, "agy")
- 40     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(583..585, "agy")
- 45     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(631..632, "cun")
- 50     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(676..678, "cgn")
- 55     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(742..744, "cgn")
- 50     (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(769..771, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(778..780, "agy")

5 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(784..786, "agy")

10 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(799..801, "agy")

15 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(805..807, "agy")

20 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(811..813, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(836..838, "cun")

25 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(871..873, "agy")

30 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(907..909, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(910..912, "agy")

35 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(919..921, "cun")

40 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(928..930, "cun")

45 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(934..936, "agy")

(ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(937..939, "cun")

50 (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(946..948, "agy")

55

- (ix) FEATURE:  
    (A) NAME/KEY: variation  
    (B) LOCATION:replace(955..957, "agy")
- 5      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(961..963, "agy")
- 10      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(982..984, "agy")
- 15      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(985..987, "cgn")
- 20      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1006..1008, "cun")
- 25      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1009..1011, "cgn")
- 30      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1021..1023, "agy")
- 35      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1030..1032, "cun")
- 40      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1084..1086, "agy")
- 45      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1087..1089, "cgn")
- 50      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1090..1092, "cun")
- 55      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1096..1098, "agy")
- 55      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1099..1101, "cun")
- 55      (ix) FEATURE:  
        (A) NAME/KEY: variation  
        (B) LOCATION:replace(1150..1152, "cun")

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

	AUGUAYUCNA UGAUGAUGGA RACNGAYUUR CAYUCNCCNG GNGGNGCNCA RGCNCCNACN	60
5	AAYUURUCNG GNCCNGCNGG NGCNGGGNGN GGNGGGNGG GNGGNGGGG NGGNGGGNGN	120
	GGNGGGNGG CNAARGCNAA YCARGAYAGR GUNAARAGRC CNAUGAAYGC NUUYAUGGUN	180
10	UCGUCNAGRG GNCARAGRAG RAARAUGGCN CARGARAAYC CNAARAUGCA YAAYUCNGAR	240
	AUHUCNAARA GRUURGGNGC NGARUCGAAR GUNAUGUCNG ARGCNGARAA RAGRCCNUUY	300
	AUHGAYGARG CNAARAGRUU RAGRGCNUR CAYAUGAARG ARCAYCCNGA YUAYAARUAY	360
15	AGRCCNAGRA GRAARACNAA RACNUURUUR AARAARGAYA ARUAYUCNUU RGCNGGGNGN	420
	UURUURGCNG CNGGNGCNGG NGGNGGGNGN GCNGCNGUNG CNAUGGGNGU NGGNGUNGNGN	480
20	GUNGNGCNG CNCCNGUNG NCARAGRUUR GARUCNCCNG GNGGNGCNGC NGGNGGNGCN	540
	UAYGCNCAYG UNAAYGGNUC GGCNAAYGGN GCNUAYCCNG GNUCNGUNG NGCNGCNGCN	600
	GCNGCNGCNG CNAUGAUGCA RGARGNCAR UURGCNUAYG GNCARCAAYC NGGNGCNGGN	660
25	GGNGCNCAYC CNCAYAGRAC NCCNGCNCAY CCNAYCCNC AYCAAYCCNCA YGCNCAYCCN	720
	CAYAAYCCNC ARCCNAUGCA YAGRUAYGAY AUGGGNGCNU URCARUAYUC NCCNAUHUCN	780
30	AAYUCNCARG GNUAYAUGUC NGCNUCNCCN UCNGGNUAYG GNGGNGUURCC NUAYGGNGCN	840
	GCNGCNGCNG CNGCNGCNGC NCAYCARAAY UCNGCNGUNG CNGCNGCNGC NGCNGCNGCN	900
	GCNGCNUCNU CNGGNGCNUU RGGNGCNUUR GGNUCNUURG UNAARUCNGA RCCNUCNGGN	960
35	UCNCCNCCNG CNCCNGCNCA YUCNAGRCN CCNUGYCCNG GNGAYUURAG RGARAUGAUH	1020
	UCNAUGUAYU URCCNGCNGG NGARGGGNGN GAYCCNGCNG CNGCNGCNGC NGCNGCNGCN	1080
40	CARUCNAGRU URCAYUCNUU RCCNCARCAY UAYCARGGNG CNGGNGCNGG NGUNAAYGGN	1140
	ACNGUNCCNU URACNCAYAU H	1161

## (2) INFORMATION FOR SEQ ID NO: 6:

- 45 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - 50 (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- 55 (iv) ANTI-SENSE: NO



5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

7

WWCAAWG

## Claims

1. A method for isolating one or more neuroblastic cells from a population of cells comprising the steps of:
- 5 (a) detecting the expression of the *Sox1* gene in the cell(s); and
- (b) sorting the cell(s) to isolate those cells expressing the *Sox1* gene.
- 10 2. A method according to claim 1, wherein the population of cells is derived from CNS tissue.
3. A method according to claim 1, wherein the population of cells is derived from a cell culture.
- 15 4. A method according to any preceding claim, wherein the expression of the *Sox1* gene is detected by nucleic acid hybridisation.
5. A method according to any one of claims 1 up to 3, wherein the expression
- 20 of the *Sox1* gene is detected by a binding of SOX1 to a detectable ligand.
6. A method according to claim 5, wherein the detectable ligand is a labelled immunoglobulin.
- 25 7. A method according to claim 5, wherein the detectable ligand is a labelled oligonucleotide complementary to *Sox1* mRNA.
8. A method according to any preceding claim, wherein the expression of the *Sox1* gene is detected by FACS analysis.

30

9. A method for isolating a neuroblastic cell from a population of cells, comprising the steps of:

(a) transfecting the population of cells with a genetic construct comprising a coding sequence encoding a detectable marker operatively linked to a *Sox1* control region;

(b) detecting the cells which express the selectable marker; and

(c) sorting the cells which express the selectable marker from the population of cells.

10. A method for isolating a neuroblastic cell from a population of cells, comprising the steps of:

(a) transfecting the population of cells with a genetic construct comprising a coding sequence encoding a detectable marker operatively linked to a control sequence which is transactivatable by SOX1;

(b) detecting the cells which express the selectable marker; and

(c) sorting the cells which express the selectable marker from the population of cells.

11. A method according to claim 9 or claim 10, wherein the selectable marker is a fluorescent or luminescent polypeptide.

12. A method according to claim 9 or claim 10, wherein the selectable marker is a polypeptide detectable at the surface of the cell.

13. A method according to claim 9, wherein the *Sox1* control sequence comprises nucleotides 1 to 60 of SEQ ID No. 3.

14. A method according to claim 10, wherein the element transactivatable by  
5 SOX1 comprises the sequence motif A/T A/T CAA A/T G.

15. A method for producing a cell committed to the neuronal lineage, comprising the steps of:

10 (a) transfecting a pluripotent stem cell with a genetic construct comprising a coding sequence expressing *Sox1*;

(b) culturing the stem cells in order to differentiate them into neural cells;  
and

15

(c) isolating the neural cells thereby produced.

16. A method according to claim 15, wherein the *Sox1* sequence is operatively linked to an inducible promoter.

20

17. A method according to claim 15 or claim 16, wherein the cell is further transfected with a vector comprising a sequence encoding a regulator which modulates the expression of the *Sox1* sequence.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 5/06, 5/08, C12Q 1/68,</b> <b>C12N 5/10, 15/85</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/00516</b> <b>(43) International Publication Date:</b> 7 January 1999 (07.01.99)
<b>(21) International Application Number:</b> PCT/GB98/01862 <b>(22) International Filing Date:</b> 25 June 1998 (25.06.98) <b>(30) Priority Data:</b> 9713469.6                      25 June 1997 (25.06.97)                      GB <b>(71) Applicant (for all designated States except US):</b> MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LOVELL-BADGE, Robin [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). PEVNY, Laryssa, H. [GB/GB]; National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA (GB). SMITH, Austin [GB/GB]; Centre for Genome Research, University of Edinburgh, East Mains Road, Edinburgh EH9 3WQ (GB). <b>(74) Agents:</b> MASCHIO, Antonio et al.; D. Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <b>(88) Date of publication of the international search report:</b> 18 March 1999 (18.03.99)
<b>(54) Title:</b> NEURONAL STEM CELL GENE  <b>(57) Abstract</b> <p>The invention relates to a method for isolating a neuroblastic cell from a population of cells comprising the steps of: (a) detecting the expression of the <i>Sox1</i> gene in the cells; and (b) sorting the cells to isolate those cells expressint the <i>Sox1</i> gene, as well as to a method for causing a cell to become committed to the neural pathway comprising administering SOX1 thereto.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01862

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N5/06 C12N5/08 C12Q1/68 C12N5/10 C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

A	WO 97 02049 A (EMORY UNIVERSITY) 23 January 1997 see the whole document ---	1-17
A	US 5 639 618 A (GAY D.A.) 17 June 1997 see the whole document ---	1-17
A	PEVNY L H ET AL: "Sox genes find their feet." CURRENT OPINION IN GENETICS AND DEVELOPMENT, (1997 JUN) 7 (3) 338-44, XP002087357 see the whole document ---	1-17

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 December 1998

Date of mailing of the international search report

28/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/01862

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>REX M ET AL: "cSox21 exhibits a complex and dynamic pattern of transcription during embryonic development of the chick central nervous system."  MECHANISMS OF DEVELOPMENT, (1997 AUG) 66 (1-2) 39-53, XP002087358  see the whole document  -----</p>	1-17
P,X	<p>DATABASE MEDLINE  US NATIONAL LIBRARY OF MEDICINE (NLM),  BETHESDA, MD, US  PEVNY L H ET AL: "A role for SOX1 in neural determination."  XP002087359  see abstract  &amp; DEVELOPMENT, (1998 MAY) 125 (10) 1967-78,  ENGLAND: United Kingdom  -----</p>	1-17



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/01862

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9702049 A	23-01-1997	US 5753505 A AU 6452196 A CA 2226417 A EP 0841950 A	19-05-1998 05-02-1997 23-01-1997 20-05-1998
US 5639618 A	17-06-1997	NONE	